Last Updated on: 26 July, 2024
About the Company - Alembic Pharmaceuticals Ltd
Alembic Pharmaceuticals Ltd. is a Public Limited Listed company incorporated on 16/06/2010 and has its registered office in the State of Gujarat, India. Company’s Corporate Identification Number(CIN) is L24230GJ2010PLC061123 and registration number is 061123. Currently Company is involved in the business activities of Manufacture of pharmaceuticals, medicinal chemical and botanical products. Company’s Total Operating Revenue is Rs. 5035.41 Cr. and Equity Capital is Rs. 39.31 Cr. for the Year ended 31/03/2022.
| Management |
|---|
| Name | Position Held |
|---|
| Mr. Chirayu Amin | Chairman & CEO |
| Mr. Pranav Amin | Managing Director |
| Mr. Shaunak Amin | Managing Director |
| Mr. R K Baheti | Director - Finance & CFO |
| Dr. Archana Hingorani | Independent Director |
| Mr. Ashok Barat | Independent Director |
| Mr. Jai Diwanji | Independent Director |
| Mr. Manish Kejriwal | Independent Director |
Basic Stock Data of Alembic Pharmaceuticals Ltd
Last Updated: July 26, 2024, 11:03 pm
| Market Cap | 23,910 Cr. |
|---|
| Current Price | 1,216 |
|---|
| High / Low | 1,225/707 |
|---|
| Stock P/E | 39.0 |
|---|
| Book Value | 245 |
|---|
| Dividend Yield | 0.90 % |
|---|
| ROCE | 13.1 % |
|---|
| ROE | 13.3 % |
|---|
| Face Value | 2.00 |
|---|
| PEG Ratio | -4.21 |
|---|
Data Source: screener.in
Competitors of Alembic Pharmaceuticals Ltd
| Stock Name | Market Cap | Current Price | High / Low | Stock P/E | Book Value | Dividend Yield | ROCE | ROE | Face Value |
|---|
| Murae Organisor Ltd | 36.1 Cr. | 1.46 | 3.10/0.90 | 722 | 2.26 | 0.00 % | 0.79 % | 0.13 % | 2.00 |
| Dipna Pharmachem Ltd | 18.6 Cr. | 7.73 | 24.1/7.46 | 17.0 | 15.6 | 0.00 % | 8.49 % | 4.47 % | 10.0 |
| Decipher Labs Ltd | 18.5 Cr. | 18.3 | 25.8/14.4 | | 21.6 | 0.00 % | 4.30 % | 7.46 % | 10.0 |
| Coral Laboratories Ltd | 255 Cr. | 715 | 748/245 | 16.0 | 497 | 0.00 % | 12.6 % | 9.58 % | 10.0 |
| Concord Drugs Ltd | 38.0 Cr. | 38.0 | 61.5/28.2 | 90.6 | 33.8 | 0.00 % | 4.54 % | 1.29 % | 10.0 |
| Industry Average | 22,026.07 Cr | 1,358.00 | | 61.59 | 206.71 | 0.33% | 17.47% | 17.04% | 6.53 |
Alembic Pharmaceuticals Ltd Quarterly Results
| Month | Dec 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Dec 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 |
|---|
| Sales | 1,314 | 1,280 | 1,326 | 1,292 | 1,272 | 1,416 | 1,262 | 1,475 | 1,509 | 1,406 | 1,486 | 1,595 | 1,631 |
| Expenses | 949 | 960 | 1,090 | 1,054 | 1,030 | 1,268 | 1,255 | 1,244 | 1,274 | 1,203 | 1,287 | 1,387 | 1,364 |
| Operating Profit | 365 | 320 | 236 | 239 | 242 | 148 | 7 | 231 | 235 | 204 | 199 | 208 | 266 |
| OPM % | 28% | 25% | 18% | 18% | 19% | 10% | 1% | 16% | 16% | 14% | 13% | 13% | 16% |
| Other Income | 3 | 25 | 2 | 21 | 19 | 10 | 1 | 0 | 0 | 1 | 12 | 10 | 3 |
| Interest | 2 | 3 | 2 | 5 | 4 | 7 | 9 | 12 | 15 | 14 | 14 | 16 | 15 |
| Depreciation | 47 | 51 | 53 | 55 | 56 | 123 | 67 | 68 | 67 | 74 | 66 | 68 | 69 |
| Profit before tax | 318 | 292 | 183 | 200 | 201 | 29 | -67 | 151 | 154 | 116 | 130 | 135 | 185 |
| Tax % | 19% | 19% | 19% | 20% | 14% | 24% | 2% | 12% | 21% | -31% | 7% | -1% | 2% |
| Net Profit | 286 | 242 | 158 | 164 | 172 | 22 | -66 | 133 | 122 | 153 | 121 | 137 | 180 |
| EPS in Rs | 14.88 | 12.75 | 8.37 | 8.34 | 8.74 | 1.12 | -3.35 | 6.78 | 6.20 | 7.76 | 6.14 | 6.95 | 9.18 |
Last Updated: July 10, 2024, 2:50 pm
Alembic Pharmaceuticals Ltd Quarterly Chart
Alembic Pharmaceuticals Ltd Profit & Loss
Last Updated: July 10, 2024, 2:50 pm
| Month | Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | TTM |
|---|
| Sales | 1,465 | 1,520 | 1,863 | 2,056 | 3,166 | 3,105 | 3,131 | 3,935 | 4,606 | 5,393 | 5,306 | 5,653 | 5,997 |
| Expenses | 1,246 | 1,268 | 1,506 | 1,653 | 2,159 | 2,490 | 2,488 | 3,061 | 3,383 | 3,913 | 4,432 | 4,970 | 5,151 |
| Operating Profit | 219 | 252 | 358 | 403 | 1,007 | 615 | 643 | 874 | 1,223 | 1,480 | 874 | 682 | 845 |
| OPM % | 15% | 17% | 19% | 20% | 32% | 20% | 21% | 22% | 27% | 27% | 16% | 12% | 14% |
| Other Income | 13 | 4 | 4 | 4 | 7 | 2 | 7 | 9 | -39 | 87 | 56 | -2 | 23 |
| Interest | 38 | 15 | 10 | 4 | 5 | 5 | 3 | 18 | 27 | 16 | 18 | 50 | 59 |
| Depreciation | 34 | 35 | 40 | 44 | 72 | 83 | 105 | 115 | 157 | 183 | 287 | 275 | 274 |
| Profit before tax | 161 | 206 | 311 | 359 | 936 | 529 | 541 | 749 | 1,000 | 1,368 | 625 | 355 | 535 |
| Tax % | 19% | 20% | 24% | 21% | 23% | 23% | 22% | 21% | 20% | 19% | 17% | 4% | |
| Net Profit | 130 | 165 | 236 | 283 | 720 | 403 | 413 | 583 | 801 | 1,146 | 521 | 342 | 532 |
| EPS in Rs | 6.90 | 8.77 | 12.49 | 15.01 | 38.20 | 21.39 | 21.89 | 31.00 | 43.97 | 58.33 | 26.50 | 17.40 | 27.05 |
| Dividend Payout % | 20% | 29% | 24% | 23% | 9% | 19% | 18% | 18% | 23% | 24% | 38% | 46% | |
Alembic Pharmaceuticals Ltd Profit & Loss Yearly Chart
Alembic Pharmaceuticals Ltd Growth
|
| Compounded Sales Growth |
|---|
| 10 Years: | 13% |
| 5 Years: | 10% |
| 3 Years: | 5% |
| TTM: | 10% |
|
| Compounded Profit Growth |
|---|
| 10 Years: | 10% |
| 5 Years: | 1% |
| 3 Years: | -19% |
| TTM: | 77% |
|
| Stock Price CAGR |
|---|
| 10 Years: | 13% |
| 5 Years: | 18% |
| 3 Years: | 14% |
| 1 Year: | 64% |
|
| Return on Equity |
|---|
| 10 Years: | 20% |
| 5 Years: | 16% |
| 3 Years: | 10% |
| Last Year: | 13% |
Last Updated: July 26, 2024, 6:36 am
Alembic Pharmaceuticals Ltd Balance Sheet
Last Updated: July 10, 2024, 2:50 pm
| Month | Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Sep 2023 |
|---|
| Equity Capital | 38 | 38 | 38 | 38 | 38 | 38 | 38 | 38 | 38 | 39 | 39 | 39 | 39 |
| Reserves | 357 | 465 | 638 | 847 | 1,560 | 1,865 | 2,182 | 2,681 | 3,182 | 5,028 | 5,198 | 4,331 | 4,431 |
| Borrowings | 353 | 187 | 109 | 264 | 114 | 89 | 708 | 1,128 | 1,747 | 584 | 717 | 722 | 869 |
| Other Liabilities | 304 | 358 | 432 | 493 | 718 | 698 | 1,013 | 931 | 1,022 | 1,058 | 1,167 | 1,090 | 1,116 |
| Total Liabilities | 1,052 | 1,048 | 1,217 | 1,641 | 2,429 | 2,689 | 3,941 | 4,778 | 5,989 | 6,709 | 7,122 | 6,183 | 6,455 |
| Fixed Assets | 268 | 344 | 397 | 547 | 708 | 799 | 993 | 1,158 | 1,552 | 1,788 | 1,798 | 2,398 | 2,603 |
| CWIP | 58 | 32 | 21 | 83 | 93 | 396 | 1,010 | 1,551 | 1,846 | 2,183 | 2,304 | 601 | 478 |
| Investments | 3 | 3 | 3 | 2 | 87 | 50 | 42 | 49 | 18 | 236 | 118 | 96 | 98 |
| Other Assets | 723 | 668 | 796 | 1,009 | 1,541 | 1,444 | 1,896 | 2,019 | 2,573 | 2,502 | 2,902 | 3,087 | 3,277 |
| Total Assets | 1,052 | 1,048 | 1,217 | 1,641 | 2,429 | 2,689 | 3,941 | 4,778 | 5,989 | 6,709 | 7,122 | 6,183 | 6,455 |
Alembic Pharmaceuticals Ltd Reserves and Borrowings Chart
Alembic Pharmaceuticals Ltd Cash Flow
| Month | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 |
|---|
| Cash from Operating Activity | 265 | 240 | 172 | 948 | 329 | 312 | 812 | 449 | 1,463 | 552 | 724 | 803 |
| Cash from Investing Activity | -67 | -81 | -256 | -307 | -486 | -884 | -756 | -731 | -840 | -372 | -448 | -321 |
| Cash from Financing Activity | -229 | -151 | 87 | -224 | -129 | 503 | 59 | 155 | -597 | -217 | -262 | -438 |
| Net Cash Flow | -31 | 8 | 3 | 417 | -286 | -69 | 115 | -127 | 26 | -37 | 14 | 45 |
|
Alembic Pharmaceuticals Ltd Financial Efficiency Indicators
| Month | Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 |
|---|
| Debtor Days | 50 | 56 | 54 | 64 | 40 | 40 | 61 | 45 | 69 | 24 | 56 | 68 |
| Inventory Days | 133 | 143 | 159 | 196 | 266 | 269 | 302 | 356 | 417 | 431 | 406 | 315 |
| Days Payable | 108 | 129 | 148 | 166 | 264 | 213 | 313 | 237 | 220 | 194 | 178 | 145 |
| Cash Conversion Cycle | 75 | 70 | 65 | 94 | 42 | 96 | 51 | 164 | 266 | 261 | 283 | 237 |
| Working Capital Days | 61 | 59 | 50 | 71 | 49 | 72 | 93 | 64 | 118 | 94 | 118 | 119 |
| ROCE % | 30% | 31% | 44% | 38% | 66% | 29% | 22% | 23% | 24% | 26% | 11% | 7% |
Alembic Pharmaceuticals Ltd Financial Efficiency Indicators Chart
Alembic Pharmaceuticals Ltd Share Holding Pattern
| Month | Jun 2021 | Sep 2021 | Dec 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 |
|---|
| Promoters | 69.48% | 69.48% | 69.48% | 69.61% | 69.61% | 69.61% | 69.61% | 69.61% | 69.61% | 69.61% | 69.61% | 69.61% |
| FIIs | 6.41% | 5.52% | 5.89% | 6.02% | 5.94% | 5.32% | 4.99% | 4.55% | 4.34% | 4.51% | 4.52% | 4.46% |
| DIIs | 11.25% | 11.42% | 11.61% | 11.74% | 12.15% | 12.55% | 12.76% | 13.32% | 13.65% | 14.22% | 14.51% | 15.39% |
| Public | 12.86% | 13.58% | 13.03% | 12.63% | 12.30% | 12.52% | 12.64% | 12.53% | 12.39% | 11.67% | 11.36% | 10.54% |
| No. of Shareholders | 1,01,686 | 1,23,059 | 1,10,038 | 1,06,437 | 1,01,457 | 1,03,811 | 1,01,864 | 99,522 | 97,607 | 89,552 | 85,212 | 76,567 |
Alembic Pharmaceuticals Ltd Shareholding Pattern Chart
No. of Alembic Pharmaceuticals Ltd Shareholders
Alembic Pharmaceuticals Ltd Mutual Fund Holdings
| Fund Name | No of Shares | AUM (%) | Amount Invested (Cr) | Previous Number of Shares | Previous Date | Percentage Change |
|---|
| DSP Mid Cap Fund | 4,766,071 | 2.23 | 355.45 | 4,766,071 | 2024-07-25 | 0% |
| Kotak Small Cap Fund - Regular Plan | 3,874,016 | 2.16 | 288.92 | 4,766,071 | 2024-07-25 | -18.72% |
| DSP ELSS Tax Saver Fund | 1,727,123 | 1.02 | 128.81 | 4,766,071 | 2024-07-25 | -63.76% |
| DSP Healthcare Fund | 1,346,066 | 5.22 | 100.39 | 4,766,071 | 2024-07-25 | -71.76% |
| DSP Small Cap Fund | 766,118 | 0.44 | 57.14 | 4,766,071 | 2024-07-25 | -83.93% |
| DSP Top 100 Equity Fund | 701,755 | 1.66 | 52.34 | 4,766,071 | 2024-07-25 | -85.28% |
| Aditya Birla Sun Life Small Cap Fund | 515,665 | 0.77 | 38.46 | 4,766,071 | 2024-07-25 | -89.18% |
| Axis Small Cap Fund | 235,652 | 0.1 | 17.57 | 4,766,071 | 2024-07-25 | -95.06% |
| Mahindra Manulife Flexi Cap Fund | 170,000 | 1.17 | 12.68 | 4,766,071 | 2024-07-25 | -96.43% |
| Aditya Birla Sun Life Pharma & Healthcare Fund | 161,138 | 2.13 | 12.02 | 4,766,071 | 2024-07-25 | -96.62% |
Alembic Pharmaceuticals Ltd ROCE Trend
Alembic Pharmaceuticals Ltd EPS Trend
Alembic Pharmaceuticals Ltd Key Financial Ratios
| Month | Mar 24 | Mar 23 | Mar 22 | Mar 21 | Mar 20 |
|---|
| FaceValue | 2.00 | 2.00 | 2.00 | 2.00 | 2.00 |
| Basic EPS (Rs.) | 31.33 | 17.40 | 26.50 | 60.81 | 43.97 |
| Diluted EPS (Rs.) | 31.33 | 17.40 | 26.50 | 60.81 | 43.97 |
| Cash EPS (Rs.) | 45.25 | 32.99 | 40.83 | 66.05 | 50.82 |
| Book Value[Excl.RevalReserv]/Share (Rs.) | 245.14 | 222.36 | 266.47 | 257.80 | 169.25 |
| Book Value[Incl.RevalReserv]/Share (Rs.) | 245.14 | 222.36 | 266.47 | 257.80 | 169.25 |
| Revenue From Operations / Share (Rs.) | 316.90 | 287.59 | 269.95 | 274.39 | 244.34 |
| PBDIT / Share (Rs.) | 48.93 | 36.18 | 47.04 | 79.75 | 65.14 |
| PBIT / Share (Rs.) | 35.05 | 22.17 | 32.45 | 70.42 | 56.80 |
| PBT / Share (Rs.) | 32.20 | 19.61 | 31.55 | 69.60 | 53.04 |
| Net Profit / Share (Rs.) | 31.38 | 18.97 | 26.23 | 56.72 | 42.47 |
| NP After MI And SOA / Share (Rs.) | 31.33 | 17.40 | 26.50 | 59.94 | 43.97 |
| PBDIT Margin (%) | 15.43 | 12.58 | 17.42 | 29.06 | 26.66 |
| PBIT Margin (%) | 11.06 | 7.70 | 12.02 | 25.66 | 23.24 |
| PBT Margin (%) | 10.15 | 6.82 | 11.68 | 25.36 | 21.70 |
| Net Profit Margin (%) | 9.90 | 6.59 | 9.71 | 20.67 | 17.38 |
| NP After MI And SOA Margin (%) | 9.88 | 6.05 | 9.81 | 21.84 | 17.99 |
| Return on Networth / Equity (%) | 12.78 | 7.82 | 9.94 | 22.97 | 25.74 |
| Return on Capital Employeed (%) | 13.80 | 9.58 | 11.79 | 25.49 | 25.26 |
| Return On Assets (%) | 9.55 | 5.53 | 7.31 | 17.56 | 13.83 |
| Long Term Debt / Equity (X) | 0.00 | 0.00 | 0.00 | 0.03 | 0.27 |
| Total Debt / Equity (X) | 0.08 | 0.14 | 0.12 | 0.03 | 0.54 |
| Asset Turnover Ratio (%) | 0.98 | 0.77 | 0.73 | 0.79 | 0.77 |
| Current Ratio (X) | 2.12 | 1.78 | 1.67 | 2.01 | 1.41 |
| Quick Ratio (X) | 0.98 | 0.87 | 0.72 | 0.85 | 0.72 |
| Inventory Turnover Ratio (X) | 0.89 | 0.86 | 0.78 | 0.93 | 0.95 |
| Dividend Payout Ratio (NP) (%) | 25.53 | 57.47 | 52.82 | 0.00 | 39.32 |
| Dividend Payout Ratio (CP) (%) | 17.69 | 31.83 | 34.06 | 0.00 | 33.05 |
| Earning Retention Ratio (%) | 74.47 | 42.53 | 47.18 | 0.00 | 60.68 |
| Cash Earning Retention Ratio (%) | 82.31 | 68.17 | 65.94 | 0.00 | 66.95 |
| Interest Coverage Ratio (X) | 17.11 | 14.17 | 52.15 | 97.85 | 45.21 |
| Interest Coverage Ratio (Post Tax) (X) | 11.98 | 8.43 | 30.08 | 70.59 | 32.09 |
| Enterprise Value (Cr.) | 19611.97 | 10301.50 | 15131.79 | 19003.45 | 11697.08 |
| EV / Net Operating Revenue (X) | 3.15 | 1.82 | 2.85 | 3.52 | 2.54 |
| EV / EBITDA (X) | 20.39 | 14.49 | 16.37 | 12.12 | 9.53 |
| MarketCap / Net Operating Revenue (X) | 3.10 | 1.72 | 2.75 | 3.52 | 2.18 |
| Retention Ratios (%) | 74.46 | 42.52 | 47.17 | 0.00 | 60.67 |
| Price / BV (X) | 4.01 | 2.23 | 2.78 | 3.70 | 3.12 |
| Price / Net Operating Revenue (X) | 3.10 | 1.72 | 2.75 | 3.52 | 2.18 |
| EarningsYield | 0.03 | 0.03 | 0.03 | 0.06 | 0.08 |
Alembic Pharmaceuticals Ltd Profitability Ratios (%)
Alembic Pharmaceuticals Ltd Liquidity Ratios
Alembic Pharmaceuticals Ltd Liquidity Ratios (%)
Alembic Pharmaceuticals Ltd Interest Coverage Ratios (%)
Alembic Pharmaceuticals Ltd Valuation Ratios
Strength and Weakness of Alembic Pharmaceuticals Ltd Stock
| Strength | Weakness |
|---|
- The stock has a high average ROCE of 29.25%, which is a positive sign.
- The company has higher reserves (2,729.67 cr) compared to borrowings (573.50 cr), indicating strong financial stability.
- The company has shown consistent growth in sales (3.15 cr) and profit (408.38 cr) over the years.
| - The stock has a high average Working Capital Days of 80.67, which may not be favorable.
- The stock has a high average Cash Conversion Cycle of 142.00, which may not be favorable.
|
FAQ
What is the latest fair value of Alembic Pharmaceuticals Ltd?
The latest fair value of Alembic Pharmaceuticals Ltd is ₹950.51.
What is the Market Cap of Alembic Pharmaceuticals Ltd?
The Market Cap of Alembic Pharmaceuticals Ltd is 23,910 Cr..
What is the current Stock Price of Alembic Pharmaceuticals Ltd as on 26 July 2024?
The current stock price of Alembic Pharmaceuticals Ltd as on 26 July 2024 is 1,216.
What is the High / Low of Alembic Pharmaceuticals Ltd stocks in FY 2024?
In FY 2024, the High / Low of Alembic Pharmaceuticals Ltd stocks is 1,225/707.
What is the Stock P/E of Alembic Pharmaceuticals Ltd?
The Stock P/E of Alembic Pharmaceuticals Ltd is 39.0.
What is the Book Value of Alembic Pharmaceuticals Ltd?
The Book Value of Alembic Pharmaceuticals Ltd is 245.
What is the Dividend Yield of Alembic Pharmaceuticals Ltd?
The Dividend Yield of Alembic Pharmaceuticals Ltd is 0.90 %.
What is the ROCE of Alembic Pharmaceuticals Ltd?
The ROCE of Alembic Pharmaceuticals Ltd is 13.1 %.
What is the ROE of Alembic Pharmaceuticals Ltd?
The ROE of Alembic Pharmaceuticals Ltd is 13.3 %.
What is the Face Value of Alembic Pharmaceuticals Ltd?
The Face Value of Alembic Pharmaceuticals Ltd is 2.00.
Disclaimer: This article is for informational purposes only and should not be construed as financial advice. The author is not a
SEBI registered financial advisor and does not have any vested interest in Alembic Pharmaceuticals Ltd. Investors are advised to conduct their own due diligence and consult with a financial professional before making any investment decisions. The information provided in this article is based on publicly available data and the author's analysis, but it may not be comprehensive or up-to-date. The author and getaka.co.in are not responsible for any errors or omissions in the content. This article is not intended to promote any particular investment strategy or recommendation, and readers should consult with their own financial advisors before making any investment decisions. Data Source:
NSE 
